AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference
Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered at this year’s Alzheimer’s Association International Conference (AAIC) which takes place virtually July 27 – 31, 2020.